ProCE Banner Activity

Advances in Precision Cancer Care for Community Practitioners: A Focus on NTRK- and RET-Altered Malignancies

Slideset Download
Download this slideset on the management of NTRK and RET-altered malignancies with targeted therapies.

Released: August 04, 2022

Expiration: August 03, 2023

Share

Faculty

Alexander E Drilon

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Thomas Stinchcombe

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Lilly

Program Director Disclosure

Program Director

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consultant/advisor/speaker fees from 14ner/Elevation Oncology, AbbVie, Amgen, Applied Pharmaceutical Science ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, Chugai Pharm, EMD Serono, EPG Health, Entos, Exelixis, Harborside, Helsinn, Hengrui, Ignyta/Genentech/Roche, Janssen, Liberum, Loxo/Bayer/Lilly, mBrace, Medendi, Merus, Monopteros, MORE Health, Nexus, Novartis, Nuvalent, Ology, Pfizer, Prelude, Remedica, Repare RX, RV More, Takeda/Ariad/Millennium, TouchIME, TP Therapeutics, Treeline Bio, Tyra Biosciences, and Verastem; and has received funds for research support (paid to institution) from Exelixis, GlaxoSmithKline, PharmaMar, Pfizer, Taiho, and Teva.

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Thomas Stinchcombe, MD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Janssen Oncology, Lilly, Medtronic, Novartis, Pfizer, Puma Biotechnology, Regeneron, Turning Point Therapeutics, Sanofi/Aventis, and Takeda and funds for research support paid to his institution from Advaxis, AstraZeneca, Genentech/Roche, Mirati, Regeneron, and Takeda.